EVOGENE LTD. (EVGN) is a publicly traded Healthcare sector company. As of May 20, 2026, EVGN trades at $0.72 with a market cap of $8.47M and a P/E ratio of 0.00. EVGN moved +0.00% today. Year to date, EVGN is -34.16%; over the trailing twelve months it is -44.48%. Its 52-week range spans $0.70 to $3.32. Analyst consensus is buy with an average price target of $2.25. Rallies surfaces EVGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Evogene expands to four pharma partnerships, secures $3.4M warrant proceeds: Evogene expanded its pharma pipeline to four partnerships, adding Systasy-LMU, Queensland University of Technology and Unravel Biosciences, and secured a second Google Cloud integration for its ChemPass AI™ platform. It expects $2.9M and $1.35M dividends from Lavie Bio and Biomica in Q2 and raised $3.4M via warrant exercises.
| Metric | Value |
|---|---|
| Price | $0.72 |
| Market Cap | $8.47M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.32 |
| 52-Week Low | $0.70 |
| Volume | 31.89K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover EVGN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.25.